Management of multiple myeloma has transformed care of patients in high-income countries. Use of proteasome inhibitor-immunomodulator (IMiD) triplets and anti-CD38–based quadruplets and routine use of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results